Clinical Trials

NCT Number: NCT06218667 Phase: PHASE1|PHASE2 Trial Summary: The researchers are doing this study to find out whether copanlisib in combination with degarelix, given before standard surgical treatment (radical prostatectomy), is a safe and effective treatment t – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Memorial Sloan Kettering Cancer Center Acronym:

NCT Number: NCT06008483 Phase: PHASE1 Trial Summary: To determine the Maximum Tolerated Dose (MTD) of CycloSam®, Samarium-153-DOTMP (Sm-153-DOTMP), a radiopharmaceutical that delivers radiation to the bone when injected, given as a tandemly administere – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): QSAM Therapeutics, Inc. Acronym:

NCT Number: NCT06250751 Phase: NA Trial Summary: To refine a remote behavioral exercise training intervention for testing in a larger randomized trial. – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Virginia Commonwealth University Acronym: BETR-PC

NCT Number: NCT06173362 Phase: PHASE2 Trial Summary: This phase II trial compares the effects, good and/or bad of abiraterone and prednisone or darolutamide alone in treating patients with prostate cancer that may have spread from where it first started – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Mamta Parikh Acronym:

NCT Number: NCT06120491 Phase: PHASE3 Trial Summary: The intention of the study is to demonstrate superiority of Saruparib (AZD5305) + physician’s choice NHA relative to placebo + physician’s choice NHA by assessment of radiographic progression-free sur – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): AstraZeneca Acronym: EvoPAR-PR01

NCT Number: NCT06205316 Phase: PHASE3 Trial Summary: This phase III trial tests the side effects of stereotactic body radiation therapy (SBRT) compared to hypofractionated radiotherapy for treating patients with prostate adenocarcinoma that has come bac – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Mayo Clinic Acronym:

NCT Number: NCT05960578 Phase: PHASE2 Trial Summary: This phase II trial tests how well golimumab and apalutamide work in treating patients with castration resistant prostate cancer. Golimumab is in a class of medications called tumor necrosis factor (T – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): University of Washington Acronym:

NCT Number: NCT05682443 Phase: PHASE1|PHASE2 Trial Summary: The goal of this clinical trial is to examine the safety and efficacy of ONC-392 in combination with lutetium Lu 177 vipivotide tetraxetan in metastatic castration resistant prostate cancer patient wh – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): OncoC4, Inc. Acronym: PRESERVE-006

NCT Number: NCT06016504 Phase: NA Trial Summary: This clinical trial aims to design and validate an adaptive virtual consultation tool (AVCT) for men with prostate cancer (PC). An AVCT utilizes health literacy assessments in combination with learnin – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Acronym:

NCT Number: NCT06016725 Phase: NA Trial Summary: This phase I trial tests the feasibility, acceptability, and preliminary effectiveness of online dietary and resistance training to improve physical function in older (greater than or equal to 65-year – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Acronym: E-PROOF